This study uncovers a previously unrecognized trafficking-dependent mechanism of drug resistance, suggesting that OCIAD2 may serve as a novel therapeutic target to overcome chemoresistance in HNSCC. This evidence concerns the gene OCIAD2 and head and neck squamous cell carcinoma.